RE:RE:RE:RE:RE:Immunogen IncONCY's Phase 1/2 GOBLET basket study that included Cohort 4 results in SCCA (anal cancer) again demonstrates that pelareorep synergizes atezolizumab in the treatment of multiple cancers with results that are significant in the pursuit of an accelerated approval, and gives any Big Pharma the evidence needed to demonstrate pelareorep's effectiveness in combination with a CPI +/- chemotherapy over other previous drug combinations in SCCA and other cancers, such as pancreatic, breast and CRC, when administered early in the treatment cycle.